|1.||Kim, Dong-Hyun: 12 articles (04/2012 - 06/2003)|
|2.||Kim, Dong Hyun: 6 articles (12/2013 - 07/2009)|
|3.||Hyun, Jin Won: 6 articles (12/2013 - 07/2009)|
|4.||Song, Gang: 5 articles (12/2015 - 12/2010)|
|5.||Kang, Kyoung Ah: 5 articles (12/2013 - 07/2009)|
|6.||Kim, Hee Sun: 5 articles (07/2013 - 07/2009)|
|7.||Hu, Tianhui: 4 articles (12/2015 - 12/2010)|
|8.||Zhang, Bing: 4 articles (12/2015 - 12/2010)|
|9.||Wei, Wei: 4 articles (04/2015 - 04/2014)|
|10.||Chang, Weon Young: 4 articles (04/2013 - 07/2009)|
08/10/2013 - "The ginsenoside compound K has pharmaceutical activities, including anti-tumor, anti-inflammatory, anti-allergic, and hepatoprotective effects. "
07/08/2009 - "These results suggest that compound K has possible application for cancer therapy when used in combination with gamma-ray radiation."
01/01/2009 - "We examined the effect of Compound K on the viabilities of various cancer cell lines using MTT assays. "
01/01/2009 - "Furthermore, the compound K-ras(LSL-G12D)/p53(LSL-R270H) mice developed tumors faster and more robustly than mice harboring a single K-ras(LSL-G12D) oncogene, as expected. "
06/01/2014 - "Cytotoxic activity assays showed compounds k and r are the potent against HCT116, HeLa, and A549 cells, moreover, compound k delayed the potent tumor inhibitory activity in a colo205 xenograft model in vivo. "
04/01/2005 - "These findings suggest that ginsenoside Rb1 can be transformed to compound K by intestinal bacteria, and compound K may be effective against inflammation."
08/01/2011 - "Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation--the key step of inflammation."
01/01/2014 - "Phytogenic compounds with anti-oxidant and anti-inflammatory properties, such as ginsenoside metabolite compound K (CK) or berberine (BBR), are currently discussed as promising complementary agents in the prevention and treatment of cancer and inflammation. "
05/01/2013 - "Compound K (CK), an intestinal metabolite of ginsenosides, has pharmacological properties such as anti-angiogenesis, anti-inflammation, anti-platelet and anti-cancer activities. "
04/01/2012 - "To address the anti-inflammatory effects of compound K in vivo, we used two brain disease models of mice: sepsis (systemic inflammation) and cerebral ischemia. "
|3.||Myocardial Ischemia (Ischemic Heart Diseases)
|5.||Lung Neoplasms (Lung Cancer)
07/08/2009 - "Pretreatment of NCI-H460 human lung cancer cells with compound K produced by intestinal bacteria enhances gamma-ray radiation-induced cell death. "
03/01/2015 - "Ginsenoside metabolite compound K enhances the efficacy of cisplatin in lung cancer cells."
07/08/2009 - "Effect of compound K, a metabolite of ginseng saponin, combined with gamma-ray radiation in human lung cancer cells in vitro and in vivo."
03/01/2015 - "To evaluate the potential of ginsenoside metabolite compound K (CK) in enhancing the anti-tumor effects of cisplatin against lung cancer cells, including cell proliferation and apoptosis, and the underlying mechanism. "
|7.||Amyloid (Amyloid Fibrils)
|9.||gluconic acid (gluconate)
|1.||Heterologous Transplantation (Xenotransplantation)